linjc16/ctgov huggingface dataset:
Electrodermal Activity and Respiration in Patients Treated With Spinal Cord Stimulation

Study Overview
=================
Brief Summary
-----------------
This study is investigating skin conductance and respiration during on and off states of the spinal cord stimulator, in patients with failed back surgery syndrome.

Official Title
-----------------
Electrodermal Activity and Respiration in Patients Treated With Spinal Cord Stimulation

Conditions
-----------------
Failed Back Surgery Syndrome

Intervention / Treatment
-----------------
* Other: SCS is switched off
* Other: SCS is switched on


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is at least 18 years old. Diagnosis of FBSS (Failed conservative treatments for pain including but not limited to pharmacological therapy and physical therapy) and currently being treated with spinal cord stimulation. Cognitive and language functioning enabling coherent communication between the examiner and the participant. Exclusion Criteria: Patients with impaired skin integrity at the fingers. Patients with major psychiatric problems.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SCS off<br> | Other: SCS is switched off<br>* Spinal cord stimulator is switched off for 12 hours<br>|
| Experimental: SCS on<br> | Other: SCS is switched on<br>* Spinal cord stimulator is on<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin conductance changes | The investigators will examine the difference in skin conductance between both measurements (SCS on versus SCS off) | Two times on the same day; once while SCS is switched off and once while SCS is switched on. Total study duration lasts one day.] | 
| Respiration rate | The investigators will examine the difference in respiration rate between both measurements (SCS on versus SCS off) | Two times on the same day; once while SCS is switched off and once while SCS is switched on. Total study duration lasts one day.] | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain intensity scores using the Visual Analogue Scale | Pain intensity score on that time on a Visual Analogue Scale (VAS) ranging from zero (no pain) towards 10 (worst possible pain) for the pain intensity. | Two times on the same day; once while SCS is switched off and once while SCS is switched on. Total study duration lasts one day.] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal cord stimulation, Electrodermal activity
Radiotherapy in Primary Mediastinal Lymphoma

Study Overview
=================
Brief Summary
-----------------
The use of Rituximab has been proposed to be useful and avoid the use of radiotherapy in diffuse large B-cell lymphoma with bulky disease.We assess efficacy of adjuvant radiotherapy in patients treated with R-CHOP

Official Title
-----------------
Adjuvant Radiotherapy in Primary Mediastinal Lymphoma in Patients That Received R-CHOP

Conditions
-----------------
Adjuvant Radiotherapy on Complete Remission Patients

Intervention / Treatment
-----------------
* Radiation: no drugs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of primary mediastinal lymphoma No previous treatment performance status < 2 HIV, Hepatis B and C negative Normal :Renal, hepatic, pulmonary and cardiac function Exclusion Criteria: pregnancy -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Radiotherapy in mediastinal lymphoma<br>Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP | |
| Radiotherapy in mediastinal lymphoma<br>Radiotherapy will no be administered in patients treated with R-CHOP | |
| Radiotherapy in primary mediastinal lymphoma<br>Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site. | Radiation: no drugs<br>* Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP<br>* Other names: no applicable;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of progression free-survival and overall survival at > 5 years | Assess if the use of adjuvant radiotherapy improve outcome in patients with primary mediastinal lymphoma treated initially with R-CHOP | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess toxicity secondary to mediastinal radiotherapy | Assess if the addition of mediastinal radiotherapy to patients who received anthracyclines can produce an increase in cardiac toxicity | > 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary mediastinal lymphoma, radiotherapy, chemotherapy, rituximab
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
This is a study of infliximab (Remicade) in subjects with Crohn's disease

Detailed Description
-----------------
Crohn's disease is a disease characterized by inflammation (the changes that happen when tissues in the body are injured) and ulceration (formation of pus) of the bowel. The purpose of this study is to investigate the safety and therapeutic effect of two different doses of an anti-TNFα (tumor necrosis factor) antibody (a protein) given multiple times compared to a single dose followed by placebo (inactive substance). The name of the antibody is infliximab (Remicade) The goal of the study is to evaluate whether patients respond longer to a single dose of infliximab or to repeated doses of infliximab. Subjects will receive an infusion of infliximab at week 0 followed by infusions of infliximab or placebo at weeks 2, 6, 14 and every 8 weeks until week 54. Patients who lose response are eligible for additional infliximab treatment.

Official Title
-----------------
ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease

Conditions
-----------------
Crohn Disease

Intervention / Treatment
-----------------
* Drug: infliximab or placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men and women >=18 years of age Diagnosis of Crohn's Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography or endoscopy Exclusion Criteria: Local manifestations of Crohn's disease such as strictures, abscesses, or other disease Surgery for bowel diversion with placement of a stoma within 3 months prior to beginning the study Positive stool culture

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: infliximab or placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reductions in the signs and symptoms of Crohn's disease |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical remission;reduction in the use corticosteroids; mucosal healing |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Crohn's Disease
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System

Study Overview
=================
Brief Summary
-----------------
This study is to collect data and learn more about the Vscan Ultrasound Imaging System. It is an observational study with no additional procedures or intervention prescribed other than using the Vscan along with a routine medical physical exam.

Detailed Description
-----------------
The study requires 2 visits to OHSU. At the first visit a cardiac physical exam will be done by a cardiologist. At a second visit, a different cardiologist will perform an ultrasound scan (as part of your standard of care) using a Vscan Ultrasound System. The first and the second visit may be done on the same day depending upon your schedule and if it's convenient for you to stay. The total exam time for both the visits, including standard exam and the study device exam will be about 45 minutes.

Official Title
-----------------
A Post-Marketing Study for On Label Evaluation of the GE Vscan Ultrasound Imaging System

Conditions
-----------------
Left Ventricular Dysfunction, Right Ventricular Dysfunction, Pulmonary Hypertension, Heart Valve Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years or older provided signed and dated informed consent and is willing to provide GE Healthcare with demographic data, cardiac medical history, information collected as part of the study New patients who have an echocardiogram less than 6 months and patients who will be undergoing an echocardiogram as part of their routine clinical care Exclusion Criteria: Pregnant less than 18 years of age. unwilling to provide informed Consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Correct Diagnosis | A comparison of the percentages of correct diagnosis by VSCAN and clinical exam using a McNemar test for matched pairs with ECHO used as the gold standard. | 2 years |
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)

Study Overview
=================
Brief Summary
-----------------
The Dyspnea-ALS-Scale (DALS-15) is a uni-dimensional scale to measure dyspnea in patients with Amyotrophic Lateral Sclerosis. It can be easily and rapidly applied. The aim of this study is to investigate reliability and validity of Turkish version of the DALS-15.

Official Title
-----------------
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)

Conditions
-----------------
Amyotrophic Lateral Sclerosis, Dyspnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 18 or above Dyspnea on exertion, dyspnea at rest, or orthopnea without evidence of pulmonary or cardiac causes of dyspnea Exclusion Criteria: Severe cognitive dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Dyspnea-ALS-Scale (DALS-15) | The scale is used to measure dyspnea in ALS patients | 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Borg Scale | A 10 point Modified Borg Scale is used to assess dyspnea in supine and standing positions. | 10 minutes | 
| Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) | It is used to assess functional stats in ALS patients. This study particularly focus on pulmonary functions and dyspnea subscale of the scale. | 15 minutes |
Study of Hemostasis During the Atrial Fibrillation Ablation Procedure

Study Overview
=================
Brief Summary
-----------------
Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial fibrillation) was interrupted a few days before the procedure in order to limit the risk of per-procedural bleeding. However, 3 recent randomized studies concerning the 3 DOACs available suggest that treatment should not be interrupted during the entire operative period. The operation therefore takes place under double anticoagulation with a direct oral anticoagulant and unfractionated heparin. Under these conditions, ACT monitoring can no longer be considered a reliable means of measuring the level of anticoagulation. It was therefore necessary to explore the hemostasis of these patients in a broad way in order to avoid any risk of overdose of UFH (Unfractionated Heparin) during the procedure.

Official Title
-----------------
Study of Hemostasis During the Atrial Fibrillation Ablation Procedure

Conditions
-----------------
Hemostasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years-old with an atrial fibrillation Operated for an atrial fibrillation procedure in the University hospital of Strasbourg Without interruption of the direct oral anticoagulant For whom extended biological assessment has been made in routine practice Exclusion Criteria: Patients who refused the use of their data for this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of hemorrhagic and thrombotic complications and correlation with the various laboratory tests |  | Files analysed retrospectively from January 01, 2019 to December 31, 2019 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACT, Atrial fibrillation, Ablation, Heparin, Direct oral anticoagulant
Burn-out Among Chinese Anaesthesiologist After COVID-19 Pandemic Peak and Its Protective Factor： a National Survey

Study Overview
=================
Brief Summary
-----------------
The investigators proposed a national representative survey to collect data of socio-demographic characteristics, level of exposure to COVID-19, depression，anxiety， ptsd， burnout and resilience of working anaesthesiologists across mainland China for the following purpose Explore the current burn-out rate of Chinese anaesthesiologists and compared it with data acquired in 2015； Explore the perceived covid-19 exposure of COVID-19 among Chinese anaesthesiologist. Explore rate of burnout, anxiety, depression, PTSD symptoms experienced by the participants Explore the protective psychosocial characteristics of burnout. (resilience) See whether covid-19 exposure contribute to higher burn out rate.

Official Title
-----------------
Burn-out Among Chinese Anaesthesiologist After COVID-19 Pandemic Peak and Its Protective Factor: a National Survey

Conditions
-----------------
Burnout

Intervention / Treatment
-----------------
* Other: resilience and institutional support


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: working anaesthesiologist in mainland China Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: resilience and institutional support|psychological inherent resilience and institutional support during COVID-19 outbreak|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Burnout | Burnout level will be measured by Maslach Burnout Inventory-Human Service Survey | data will be retrieved and recored 1 week after survey distribution |
The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to assess the clinical efficacy of topical minocyclin in managing of symptoms associated with oral lichen planus (OLP). The rationale of the study is based on our previous studies demonstrating the beneficial effect of minocyclin mouthwash on recurrent aphthous stomatitis. The planned study will be a randomized controlled, cross-over trail. Patients with symptomatic OLP will randomly receive minocycline or dexamethasone rinses. The patients will rinse and expectorate 5 ml of the 1st mouthwash 4 times daily for 14 days. Subjects will complete a daily follow-up form that includes data regarding the daily intensity of pain (using VAS) caused by OLP and regarding possible side effects. After a washout period (at least 14 days) the patients will repeat the protocol with the second mouthwash.

Official Title
-----------------
The Efficacy of Topical Minocycline in Managing Symptomatic Oral Lichen Planus. A Randomized Controlled Trial

Conditions
-----------------
Oral Lichen Planus

Intervention / Treatment
-----------------
* Drug: Minocycline
* Drug: Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OLP patients (Biopsy proven) Exclusion Criteria: Known allergy to Dexamethasone or Minocycline Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dexamethasone<br>Dexamethasone 0.01% mouthwash | Drug: Dexamethasone<br>* Dexamethasone 0.01% mouthwash<br>|
| Experimental: Minocycline<br>Minocycline 0.2% mouthwash | Drug: Minocycline<br>* Minocycline 0.2% mouthwash<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptoms relief |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral lichen planus, Minocycline, Dexamethasone
Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients

Study Overview
=================
Brief Summary
-----------------
This is a prospective cohort study investigating cardiac function and cardiac biomarkers in patients with acute Aneurysmal Subarachnoid Haemorrhage (aSAH). The aims of the study are to document the incidence of myocardial dysfunction,to find the predictive factors of myocardial dysfunction, describe heart rate variability and to assess the impact of all cardiac problems on morbidity and mortality.

Detailed Description
-----------------
Laboratory markers daily: Routine laboratory test (blood gases, haemoglobin, thrombocytes, leukocytes, INR, bilirubin, creatinine, c-reactive protein, CK, CK-MB, Tnt, BNP, sodium, potassium, magnesium) are taken at 8 a.m. Study laboratory tests (sensitive ischemia markers, remodelling marker MMP-9 and CgA as surrogate marker for increased sympathetic activity) are taken four times during study period at the same time as cardiac ECHOes and Holtering. Gene sample is taken once on day one. Primary outcome measurement is to document the incidence of myocardial dysfunction and the predictive factors during the hospital stay and at three months. Secondary outcome is to assess the impact of cardiac problems on morbidity and mortality during first three months.

Official Title
-----------------
Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients

Conditions
-----------------
Aneurysmal Subarachnoid Heamorrhage, Nontraumatic Subarachnoid Haemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with nontraumatic subarachnoid haemorrhage Age > 18 years Aneurysmal bleeding Exclusion Criteria: No consent Age < 18 years Anticipated brain death < 24 hours Otherwise moribund patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| subarachnoid haemorrhage<br>nontraumatic subarachnoid haemorrhage | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cardiac failure and the impact of cardiac problems on morbidity | The aims of the study are: to document the incidence of myocardial dysfunction to find the predictive factors of myocardial dysfunction as determined by the severity aneurysmal bleeding (Hunt and Hess-grading, Glasgow coma score, Fisher scale) and demographic factors to find predictive factors for myocardial dysfunction as determined by laboratory findings, electrocardiography, and echocardiography to describe heart rate variability to assess the impact of all cardiac problems on morbidity | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
subarachnoid haemorrhage, cardiopulmonary complications